Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biot ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

PresentationGood afternoon, and welcome to the Equillium Bio Virtual KOL Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Equillium website following the conclusion of the event.Bruce SteelCo-Founder, CEO & Director Thank you very much. Good morning and/or good afternoon to everybody for joining today. We greatly appreciate you taking your time to learn more about the aryl hydrocarbon receptor and our EQ504 program. We will, during the cou ...

Virtual KOL Event to Discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis 1 November 5, 2025 Forward-Looking Statements and Other Disclaimers 3 This presentation contains forward-looking statements about Equillium, Inc. (the "Company"). In some cases, you can identify forward-looking statements by the words "will," "expect," "intend," "plan," "objective," "believe," "estimate," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable termi ...

LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of Equillium’s Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase a total of 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approved the st ...

Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitisLA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced they will host a virtual key opinion leader (KOL) event on Wednes ...

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates. “The updates we announced today mark an important and timely step as we sharpen our therapeutic pipeline focus on advancing EQ504, our novel aryl hyd ...

生物技术板块盘后表现 - 多只生物技术公司股票在周一盘后交易中强劲上涨，受临床进展、战略调整和即将到来的催化剂推动 [1] - 成交量激增和盘后新闻推动价格上涨，为常规交易时段的潜在后续走势奠定基础 [1] Cassava Sciences (SAVA) - 公司股票在盘后交易中飙升37.1%至3.18美元，常规交易时段收盘价为2.32美元，涨幅为1.75% [2] - 此次大幅波动伴随异常高的成交量，超过1100万股换手，远高于日均约100万股的成交量 [2] - 上涨动力源于市场对其研发管线重新产生兴趣，特别是其研究药物simufilam，公司近期报告了支持其治疗TSC相关癫痫新方向的临床前数据 [3] - 公司领导层变动，包括任命Joseph Hulihan博士为首席医疗官，标志着临床优先事项的战略转向 [3] - 公司参与近期生物技术会议，表明其正围绕新兴治疗应用重塑叙事 [4] Helius Medical Technologies (HSDT) - 公司股票在盘后交易中上涨15.67%至18.53美元，常规交易时段收盘价为16.02美元，当日下跌33.61% [4] - 盘后反弹伴随大量成交量和市场对其近期战略发展的重新关注 [4] - 公司宣布获得Pantera Capital和Summer Capital支持的5亿美元私募配售，以启动一个专注于Solana的国库工具，这标志着其核心神经技术业务的重大转向 [5] - 公司继续推进其医疗器械管线，便携式神经调控刺激器（PoNS）近期完成了一项卒中注册项目并取得积极结果，正准备根据突破性器械认定向FDA提交申请 [6] Werewolf Therapeutics (HOWL) - 公司股票在盘后交易中延续涨势，上涨9.78%至2.02美元，常规交易时段收盘价为1.84美元，涨幅为23.49% [6] - 此次波动伴随超过200万股的成交量，显著高于日均成交量，表明市场对其近期发展兴趣升温 [6] - 公司正通过其专有的INDUKINE平台推进多个条件激活的细胞因子疗法，其主要候选药物WTX-124目前正处于针对晚期实体瘤（包括皮肤黑色素瘤）的1/1b期试验阶段 [7] - 该研究的期中数据预计在2025年第四季度公布，这可能成为公司股票的关键拐点 [7] - 公司管理层在H C Wainwright第27届全球投资会议上重申了临床数据公布的时间表，并概述了其管线的进展 [8] - 公司上月公布第二季度业绩，净亏损1798万美元，并确认其现金状况足以支持运营至2026年 [8] Aytu BioPharma Inc (AYTU) - 公司股票在盘后交易中上涨7.63%至2.68美元，常规交易时段收盘价为2.49美元，涨幅为2.05% [8] - 此次波动伴随近两倍于日均成交量的交易量，表明在关键公司更新前市场关注度回升 [8] - 价格变动紧随公司宣布将于2025年9月23日公布2025财年全年及第四季度业绩之后 [9] - 即将发布的财报预计将阐明其商业表现以及EXXUA（一种通过与Fabre-Kramer制药公司独家协议近期获得的缓释抗抑郁药）的进展 [9] - 公司近期延长了与Eclipse的贷款协议，从而增强了流动性以支持其商业化努力 [10] Equillium Inc (EQ) - 公司股票在盘后交易中上涨10.34%至1.60美元，常规交易时段收盘价为1.45美元，下跌0.68% [10] - 反弹伴随温和成交量，此前一个月经历了波动加剧和零星价格飙升 [10] - 公司近期宣布获得高达5000万美元的融资，以推进其新型芳烃受体调节剂EQ504进入临床开发阶段 [11] - EQ504已在多个免疫学会议的海报展示中受到关注，并且公司已收到FDA关于其监管路径的反馈 [11] - 其主要候选药物itolizumab（EQ001）针对急性移植物抗宿主病的3期试验仍在进行中，并已完成针对狼疮性肾炎和溃疡性结肠炎的早期研究 [11]

研发进展 - EQ504在临床前阶段针对溃疡性结肠炎的研究，预计在2026年下半年发布顶线数据[8] - EQ001（itolizumab）获得FDA快速通道和孤儿药资格，正在评估临床推进和合作的选项[8] - EQ302（IL-15/21抑制剂）处于临床前阶段，针对胃肠道适应症[8] - EQ504的EC50为0.67nM，显示出强大的AhR调节活性[54] - EQ504的关键IND启用研究已完成，并已生产出2kg的GMP材料[56] - EQ504的临床开发计划包括进行SAD/MAD机制研究，预计将显著降低项目风险[64] - EQ504在小鼠中有效治疗DSS诱导的结肠炎，具有保护肠道屏障功能和促进肠上皮伤口愈合的作用[56] - EQ504在DSS诱导的结肠炎模型中以1 mg/kg的剂量显示出显著疗效，p<0.001[111] - EQ504通过增加CYP1A1和抗炎细胞因子的表达，激活AhR通路[113] - EQ504在小鼠DSS结肠炎模型中减少了炎症和免疫浸润，保护了结肠形态[116] 市场机会 - 针对溃疡性结肠炎的市场机会预计到2030年将超过120亿美元，安全有效的口服药物将扩大治疗患者的范围[74] - 目前在美国市场上，针对一线急性移植物抗宿主病（aGVHD）的药物销售接近10亿美元[7] - 公司在美国约有90万名患者，600,000名正在接受治疗，显示出巨大的市场潜力[75] - 约有5000名患者每年在美国发展为急性GVHD，且急性GVHD患者的死亡率仍然很高[152] - 目前没有批准的急性GVHD一线治疗药物，市场机会巨大[150] 产品效果 - EQ504在临床试验中显示出高达50%的临床缓解率，相较于现有疗法的缓解率（生物制剂约28%）具有明显优势[69] - Itolizumab在Day 29的完全缓解率为29.1%，而安慰剂组为0.0%[130] - Itolizumab在Day 99的完全缓解率为44.9%，安慰剂组为28.6%，p=0.0354[133] - Itolizumab的中位完全缓解持续时间为336天，而安慰剂组为72天，具有统计学意义[135] - Itolizumab组的死亡率为24.4%，而安慰剂组为32.5%[143] 财务状况 - 截至2025年3月31日，公司总现金和投资为1450万美元，2024年运营现金使用为1900万美元[92] 新策略 - 公司在FDA的指导下，针对炎症的靶向治疗策略日益清晰，特别是在乳糜泻方面的战略兴趣增加[7] - 乳糜泻的治疗方法包括麸质修饰、恢复肠道屏障功能、促进免疫耐受和减少炎症[199] - IL-15/IL-21通路的抑制有助于维护肠道上皮的健康[194]